Daewoong Pharmaceutical...that it has received approval from the Ministry of Food and Drug Safety (MFDS) for a phase 3 investigational new drug (IND) application evaluating Fexuclue Tab 40 mg (fexuprazan hydrochloride) for the treatment of gastric ulcers (Korea Biomedical Review) - Jun 24, 2026 - "The phase 3 study will enroll 384 patients with gastric ulcers in a multinational, multicenter, randomized, double-blind, active-controlled, parallel-group trial."
New P3 trial • Gastrointestinal Disorder
|